Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263144 | 0.95 | TAAR1 (0.50) | MAOBTAAR1FDFT1MEN1KMT2A | |
| SCHEMBL14263245 | 0.85 | MAOB (0.59) | MAOBKIF11ALDH1A1 | |
| SCHEMBL14274243 | 0.81 | MAOB (0.58) | MAOBTAAR1FDFT1MEN1KMT2A | |
| SCHEMBL14263158 | 0.79 | KCNH2 (0.44) | TAAR1FDFT1KCNH2IDO1ALDH1A1 | |
| SCHEMBL14263233 | 0.79 | TAAR1 (0.42) | MAOBTAAR1 | |
| SCHEMBL23134263 | 0.78 | TAAR1 (0.47) | MAOBTAAR1MEN1KMT2AKCNH2 | |
| SCHEMBL23134271 | 0.78 | MEN1 (0.44) | MAOBTAAR1FDFT1MEN1KMT2A | |
| SCHEMBL14263242 | 0.77 | MAOB (0.48) | MAOBTAAR1MEN1KMT2A | |
| SCHEMBL14274195 | 0.77 | CYP4F2 (0.38) | MAOBKMT2AKIF11 | |
| SCHEMBL12964410 | 0.77 | IDO1 (0.57) | MAOBTAAR1MEN1KMT2AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAOB 2920/4885TAAR1 596/4885FDFT1 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.